Format
Sort by
Items per page

Send to

Choose Destination

Best matches for bdnf major depressive:

Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study. Rocha RB et al. J Psychiatr Res. (2016)

DNA Methylation in Major Depressive Disorder. Pishva E et al. Adv Exp Med Biol. (2017)

Advances in biomarkers of major depressive disorder. Huang TL et al. Adv Clin Chem. (2015)

Search results

Items: 1 to 20 of 843

1.

Proteomic analysis of olfactory bulb suggests CACNA1E as a promoter of CREB signaling in microbiota-induced depression.

Huang C, Yang X, Zeng B, Zeng L, Gong X, Zhou C, Xia J, Lian B, Qin Y, Yang L, Liu L, Xie P.

J Proteomics. 2018 Dec 3. pii: S1874-3919(18)30421-4. doi: 10.1016/j.jprot.2018.11.023. [Epub ahead of print]

PMID:
30521978
2.

VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.

Jiang C, Lin WJ, Labonté B, Tamminga CA, Turecki G, Nestler EJ, Russo SJ, Salton SR.

Neuropsychopharmacology. 2018 Nov 20. doi: 10.1038/s41386-018-0277-4. [Epub ahead of print]

PMID:
30504797
3.

Activation of the hippocampal AC-cAMP-PKA-CREB-BDNF signaling pathway using WTKYR in depression model rats.

Peng Y, Zhang C, Su Y, Wang Z, Jiang Y.

Electrophoresis. 2018 Dec 4. doi: 10.1002/elps.201800381. [Epub ahead of print]

PMID:
30511424
4.

BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response.

Lieb K, Dreimüller N, Wagner S, Schlicht K, Falter T, Neyazi A, Müller-Engling L, Bleich S, Tadić A, Frieling H.

Front Psychiatry. 2018 Oct 26;9:511. doi: 10.3389/fpsyt.2018.00511. eCollection 2018.

5.

The Role of Dendritic Brain-Derived Neurotrophic Factor Transcripts on Altered Inhibitory Circuitry in Depression.

Oh H, Piantadosi SC, Rocco BR, Lewis DA, Watkins SC, Sibille E.

Biol Psychiatry. 2018 Oct 9. pii: S0006-3223(18)31897-3. doi: 10.1016/j.biopsych.2018.09.026. [Epub ahead of print]

PMID:
30449530
6.

Could a blood test for PTSD and depression be on the horizon?

Aspesi D, Pinna G.

Expert Rev Proteomics. 2018 Dec;15(12):983-1006. doi: 10.1080/14789450.2018.1544894. Epub 2018 Nov 20.

PMID:
30394136
7.

Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective.

Hashimoto K.

Front Pharmacol. 2018 Oct 16;9:1182. doi: 10.3389/fphar.2018.01182. eCollection 2018. Review.

8.

Loss of Microglia and Impaired Brain-Neurotrophic Factor Signaling Pathway in a Comorbid Model of Chronic Pain and Depression.

Zhu C, Xu J, Lin Y, Ju P, Duan D, Luo Y, Ding W, Huang S, Chen J, Cui D.

Front Psychiatry. 2018 Oct 4;9:442. doi: 10.3389/fpsyt.2018.00442. eCollection 2018.

9.

Hesperidin attenuates depression-related symptoms in mice with mild traumatic brain injury.

Kosari-Nasab M, Shokouhi G, Ghorbanihaghjo A, Abbasi MM, Salari AA.

Life Sci. 2018 Nov 15;213:198-205. doi: 10.1016/j.lfs.2018.10.040. Epub 2018 Oct 21.

PMID:
30352242
10.

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Youdim MBH.

J Neural Transm (Vienna). 2018 Nov;125(11):1719-1733. doi: 10.1007/s00702-018-1942-9. Epub 2018 Oct 19. Review.

PMID:
30341696
11.

The TRKB rs2289656 genetic polymorphism is associated with acute suicide attempts in depressed patients: A transversal case control study.

Deflesselle E, Colle R, Rigal L, David DJ, Vievard A, Martin S, Becquemont L, Verstuyft C, Corruble E.

PLoS One. 2018 Oct 11;13(10):e0205648. doi: 10.1371/journal.pone.0205648. eCollection 2018.

12.

Aerobic exercise program with or without motor complexity as an add-on to the pharmacological treatment of depression - study protocol for a randomized controlled trial.

Neves LM, Silva-Batista C, Marquesini R, da Cunha TF, Dimateo E, Nascimento L, Moreira-Neto A, de Lima Miliatto AC, das Chagas Mendes S, Saad F, Codogno JS, Nunes RH, Ritti-Dias RM, Juday V, Lafer B, Ugrinowitsch C.

Trials. 2018 Oct 10;19(1):545. doi: 10.1186/s13063-018-2906-y.

13.

Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder.

Sorri A, Järventausta K, Kampman O, Lehtimäki K, Björkqvist M, Tuohimaa K, Hämäläinen M, Moilanen E, Leinonen E.

Brain Behav. 2018 Nov;8(11):e01101. doi: 10.1002/brb3.1101. Epub 2018 Oct 1.

14.

Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder.

Lin CC, Tsai MC, Lee CT, Sun MH, Huang TL.

Psychiatry Res. 2018 Sep 13;270:232-237. doi: 10.1016/j.psychres.2018.09.025. [Epub ahead of print]

PMID:
30269040
15.

Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment.

Mondal AC, Fatima M.

Int J Neurosci. 2018 Nov 27:1-14. doi: 10.1080/00207454.2018.1527328. [Epub ahead of print]

PMID:
30235967
16.

Suggested Biomarkers for Major Depressive Disorder.

Hacimusalar Y, Eşel E.

Noro Psikiyatr Ars. 2018 May 28;55(3):280-290. doi: 10.5152/npa.2017.19482. eCollection 2018 Sep. Review.

17.

The effect of exercise on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF) in major depressive disorder: A meta-analysis.

Dinoff A, Herrmann N, Swardfager W, Gallagher D, Lanctôt KL.

J Psychiatr Res. 2018 Oct;105:123-131. doi: 10.1016/j.jpsychires.2018.08.021. Epub 2018 Sep 6. Review.

PMID:
30219561
18.

Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients.

Wu C, Zhao Y, Liu Y, Yang X, Yan M, Min Y, Pan Z, Qiu S, Xia S, Yu J, Yang P, Wan B, Shao Q.

Oncol Lett. 2018 Oct;16(4):5375-5382. doi: 10.3892/ol.2018.9243. Epub 2018 Jul 31.

19.

The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.

El-Haggar SM, Eissa MA, Mostafa TM, El-Attar KS, Abdallah MS.

Psychother Psychosom. 2018;87(6):331-339. doi: 10.1159/000492619. Epub 2018 Sep 11.

PMID:
30205379
20.

Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.

Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, Lener MS, Zarate CA Jr.

Int J Neuropsychopharmacol. 2018 Sep 1. doi: 10.1093/ijnp/pyy051. [Epub ahead of print]

PMID:
30184133

Supplemental Content

Loading ...
Support Center